$7.20
-0.77-9.66%
Last update: Nov 5, 6:16 PM
Immix Biopharma Inc
IMMXNASDAQ
The average analyst price target for Immix Biopharma is $24, 230.1% above the current price. Of 7 analysts, 7 rate it Buy. Targets range from $19 to $30. The latest change came on Sep 29, 2026, when Needham raised its price target on Immix Biopharma from $21 to $30 and kept a Buy rating.
Price Target Range — 9 Quarters
Analyst Consensus — 7 Analysts
Rating Trend — Last 9 Months
